Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kaiwa Lui

Optometrist Irvine, CA Doctor of Optometry

NPI 1801147624 CMS profile 1240072

4940 Irvine Blvd, Ste 102, Irvine, CA 92620

Open in the dashboard

General payments

$15,377

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kaiwa Lui of Irvine, CA is reported in the CMS Open Payments database as having received $15,377 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $718 9
2024 General $208 6
2023 General $243 7
2022 General $1,005 29
2021 General $11,579 12
2020 General $335 9
2019 General $1,290 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kaiwa Lui
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Kaiwa Lui were reported at $718. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Kaiwa Lui Optometrist median Middle half National median
2019 $1,290 $159 $67–$371 $163
2020 $335 $72 $29–$165 $114
2021 $11,579 $125 $46–$292 $132
2022 $1,005 $162 $66–$374 $149
2023 $243 $177 $72–$406 $160
2024 $208 $188 $77–$427 $164
2025 $718 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $11,538 16 payments
  2. Bausch & Lomb, a division of Bausch Health US, LLC $711 9 payments
  3. Johnson & Johnson Vision Care, Inc. $546 23 payments
  4. Visioneering Technologies, Inc. $538 12 payments
  5. Bausch & Lomb Americas Inc. $499 10 payments
  6. Alcon Vision LLC $339 7 payments
  7. Optos, Inc. $288 4 payments
  8. MacuLogix, Inc. $151 2 payments
  9. Glaukos Corporation $151 1 payment
  10. Allergan Inc. $130 2 payments
  11. Other $487 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,000 1 payment
  2. Food and Beverage $4,099 88 payments
  3. Entertainment $278 3 payments
Products named General payments · program years 2019–2025
  1. MiSight Contact Lens $11,261 8 payments
  2. Acuvue $521 22 payments
  3. INFUSE $396 10 payments
  4. ULTRA MULTIFOCAL TORIC $371 3 payments
  5. P200DTx $203 3 payments
  6. P200T $203 3 payments
  7. P200TE $203 3 payments
  8. P200TxE $203 3 payments
  9. BIOTRUE ONE DAY $193 4 payments
  10. ULTRA $174 3 payments
  11. Other $2,868 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Optometry: 120

Drug cost

$57

Median for Optometry: $8,864

Branded share of claims

0%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Latanoprost Generic 16 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$20,177

Medicare's payments for the services billed

Medicare patients

57

Average age 75

Services billed

345

30 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Cancer 32%
Arthritis 32%
Diabetes 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record